Defensosomes: A biomimetic polyantimicrobial therapy
|AFFILIATION:||Houston Methodist Research Institute, Houston, Texas, United States|
Track: Medical & Biotech
Area: Advanced Material Platforms
Tech Readiness: TRL 5
Tech Brief: Broad-spectrum antimicrobials are administered to both military and civilian patients during hospitalization, leading to the evolution of multidrug resistant organisms. We will employ a new class of biomimetic antimicrobial peptides, named “defensins”, encapsulated in biomimetic drug delivery nanovescicles (defensosomes) for the selective delivery to inflamed tissues.
Value Proposition: Infectious complications continue to be common among injured combatants. Today, 75% of all war injuries are the result of explosives, which are known to lead to significant blast and burn injuries. Patients injured with larger explosives and those severely injured are at greater risk of developing infections. Data from the JTTR and the Trauma Infectious Disease Outcome Study show that 25% of casualties were found to develop an infection and those admitted to the ICU are infected 50% of the time. Data obtained from Brooke Army Medical Center reveal that between January and June of 2006, 223 OIF/OEF persons were evaluated at Brooke Army Medical Center with 66 (30%) evaluated for orthopedic-related trauma, of which 26 (40%) received courses of antibiotics for various bacteria, including ABC, Klebsiella spp., P. aeruginosa, Enterobacter spp., and methicillin resistant S. aureus (MRSA). These staggering numbers suggest that an alternative approach must be sought in order to overcome the continuation of resistance and infectious sequela of war wounds. We believe that the use of Defensosomes for the treatment of infections caused by MDROs will ensure an earlier return to function and less complications for the military personnel.
Org Type: Academic/Gov Lab